Gilead Sciences is an international biopharmaceutical company that is involved in the development and commercialisation of innovative therapies in the field of unmet medical needs such as the treatment of severe systemic and/or deep fungal infections.

As interim consultant Mark devoted his efforts on:

  • AmBisome® (liposomal Amphotericin B).

In close collaboration with the responsible product manager, his activities chiefly involved:

  • visiting academic centres and selected peripheral hospitals;
  • personal relations with hospital pharmacies, medical microbiologists, intensivists and haematologists;
  • the promotion of the use of AmBisome® for severe systemic and/or deep fungal infections by explaining and spreading scientific reference literature, protocols and other relevant documents such as the policy regulation for expensive medicines;
  • the gathering of market information to support the budget strategy for AmBisome® in 2011 and 2012.